Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating DNA, Circulating RNA, Circulating Tumor Cells

Shannon Stott's Biography



Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

Professor Stott is a Mechanical Engineer that has been working at the interface of technology and medicine. She has an extensive background in microfluidics, optics, and tissue engineering, with a focus on their applications in clinical medicine. As a postdoctoral fellow, she invented the herringbone circulating tumor cell chip (HBCTC-Chip) a device that can successfully capture extremely rare cancer cells circulating in the blood stream cancer patients. Manipulating blood flow for the isolation and separation of biological components has been a hallmark of her work and recent efforts include using nanofluidics to separate extracellular vesicles and nucleic acids from patient samples. The overriding goal of the Stott Laboratory is to use all of these technologies and techniques to improve patient lives through early diagnosis and a greater understanding of how cancer spreads and kills. Dr. Stott has a particular interest in brain tumors and the potential impact of a blood biopsy for adult and pediatric patients.

Shannon Stott Image

Microfluidic Isolation and Molecular Characterization of Glioblastoma Extracellular Vesicles

Tuesday, 24 March 2015 at 14:30

Add to Calendar ▼2015-03-24 14:30:002015-03-24 15:30:00Europe/LondonMicrofluidic Isolation and Molecular Characterization of Glioblastoma Extracellular VesiclesSELECTBIOenquiries@selectbiosciences.com

Extracellular vesicles (EVs) released from cancer cells into the bloodstream contain genetic information about the primary tumor. These EVs have the potential to be used for early diagnosis as well as to guide treatment, but can be challenging to reliably assay due to the heterogeneous population of MVs released from normal cells.  We have taken a microfluidic approach to isolate these tumor derived MVs from serum from glioblastoma patients. In this talk, I will describe our latest technology for EV capture as well as the results of our molecular analysis of these EVs. Our data demonstrates that tumor-derived MVs can be selectively captured from serum, providing a less invasive method to obtain genetic information about the patient’s tumor.


Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating DNA, Circulating RNA, Circulating Tumor CellsSELECTBIOenquiries@selectbiosciences.com